Issue 69 | April 2018
Pfizer is closing its neuroscience unit, effectively ending its research into Alzheimer’s and Parkinson’s, and intends to reallocate funding to areas where it thinks it can make a bigger impact. We reflect on the difficulties involved in improving treatment options for those suffering from degenerative neurological conditions, looking at previous Pfizer attempts to develop drugs and today’s research landscape.
We also take a look at the world’s pharma manufacturing hotspots, consider the obstacles on the road to developing a universal flu vaccine, and speak to researchers at Cardiff University who have developed a tool to systematically test the likelihood that a drug will undergo ‘racemisation’, i.e. turning into an inert or even dangerous version of itself once it enters the body.
Finally, we explore the use of growth drugs in unmet clinical needs and as a solution to cosmetic issues, and find out more about a new method of screening a person’s diverse set of antibodies, which could unlock the potential for rapid therapeutic discoveries.
Editor | Katie Woodward
Group Editor | Susanne Hauner
Commissioning Editor | Daniel Garrun
Writers | Siniša Belina, Elly Earls, Chris Lo,
Abi Millar, Dr Andrew Rut
Magazine Designer | Lorena Martinez
Graphic Designers | Paulius Zutautas, Francesco Cianciulli, Marzia Compassi, Kate Cuntapay, Anett Arc, Sara Basto
Lead Designer | John Hammond
Digital Publishing Director | Duncan West
Sales Manager | Nimai Amin
+44 (0) 207 936 6453
Deputy Editor | Callum Tyndall
Pharma Technology focus
is powered by h5mag
read past issues of pharma technology focus HERE
Pharma Technology Focus is a product of Net Resources International. Copyright 2018 Net Resources International, a trading division of Kable Intelligence Limited. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registrationnumber 03171601.
All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.